Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Galapagos  /  Galapagos 200 euro per aandeel

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Galapagos AEX:GLPG.NL, BE0003818359

  • 27,180 19 apr 2024 17:35
  • -0,200 (-0,73%) Dagrange 26,860 - 27,280
  • 62.640 Gem. (3M) 80,1K

Galapagos 200 euro per aandeel

957 Posts
Pagina: «« 1 ... 37 38 39 40 41 ... 48 »» | Laatste | Omlaag ↓
  1. [verwijderd] 25 februari 2019 21:26
    Gilead is counting on additional positive data for filgotinib, which the company is co-developing with Galapagos, after trumpeting in September how the JAK1 inhibitor candidate met its primary endpoint in the Phase III FINCH 2 trial in adults with moderate-to-severe active rheumatoid arthritis (RA) and prior inadequate response/intolerance to biologic agents. Gilead is also planning to announce Phase II and III results for its nonalcoholic steatohepatitis (NASH) candidate selonerstib in the first half of this year.

    10 Takeover Targets to Watch in 2019
    Blockbuster deals suggest a healthy year for biopharma M&A

    By Alex Philippidis - January 28, 2019

    www.genengnews.com/featured/10-takeov...
  2. [verwijderd] 25 februari 2019 21:51


    Galapagos (GLPG)

    When it comes to late-stage biotech stocks or really any drug manufacturer, pipeline means everything. It’s what drives your valuation and future potential. Luckily for clinical-stage firm Galapagos (NASDAQ:GLPG), its pipeline is very robust indeed. GLPG has multiple late-stage programs as well as 25 different drugs in discovery/early trial stages. But what separates Galapagos is that that pipeline is actually churning out real results.

    Partnering with biotech-giant Gilead (NASDAQ:GILD), GLPG’s Filgotinib is quickly becoming a winner and after impressive phase-3 data, the duo has moved closer to marketing the drug rheumatoid arthritis. At the same time, Galapagos has scored wins in cystic fibrosis, idiopathic pulmonary fibrosis, systemic sclerosis and a fast-track designation for its osteoarthritis treatment.

    All in all, GLPG has many shots on goal to make it. That’s very important to a clinical-stage biotech stock. And yet, last years rout of the sector sent shares of GLPG downwards and they’ve stayed that way. Today, Galapagos is still about 17% below its 2018 peak of $117 per share.

    Given its huge pipeline — that is increasingly winning in trials — that difference may not last long. When it comes to clinical stage biotech stocks, GLPG is one you must own.

    Feb 25, 2019, 3:25 pm EST
    5 Clinical Stage Biotech Stocks to Buy
    There's plenty of potential in clinical-stage biotech stocks

    investorplace.com/2019/02/5-clinical-...
  3. [verwijderd] 25 februari 2019 23:46
    Concurrent van Filgotinib faalt.

    Filgotinib vergroot hiermee zijn marktpotentie

    Xeljanz, Xeljanz XR (tofacitinib): Safety Communication - Safety Trial Finds Increased Risk of Blood Clots in the Lungs and Death with Higher Dose in Rheumatoid Arthritis Patients

    www.fda.gov/Safety/MedWatch/SafetyInf...
  6. [verwijderd] 1 maart 2019 00:24
    These 10 New Drugs Expected In 2019 Are On The Blockbuster Track

    A series of drugs expected to launch in 2019 could become blockbuster drugs in the next five years, according to a recent report.

    Inflammation: A Key Area For Blockbuster Drugs?

    Inflammation drugs are expected to account for nearly half of that $18 billion-plus in 2024 sales from expected blockbuster drugs.

    AbbVie (ABBV) and Gilead Sciences (GILD) with its partner Galapagos (GLPG) are going up against one another with experimental drugs called upadacitinib and filgotinib.

    Both belong to a class known as janus kinase 1 inhibitors, or JAK1 inhibitors. These drugs aim to block a pathway tied to inflammation in the body.

    AbbVie's upadacitinib is already under review at the FDA as a rheumatoid arthritis treatment. The pharma giant is also studying upadacitinib in eczema, Crohn's disease, psoriatic arthritis, ulcerative colitis and axial spondyloarthritis, a series of chronic inflammatory diseases.

    Fastest Mover

    Gilead and Galapagos are furthest along in testing filgotinib in rheumatoid arthritis, ulcerative colitis and Crohn's disease. But the duo is also looking at the JAK1 inhibitor as a potential treatment for eight other diseases.

    EvaluatePharma estimates upadacitinib could bring in $2.18 billion in 2024 sales, with filgotinib trailing at $1.49 billion.

    www.investors.com/news/technology/new...
  7. [verwijderd] 4 maart 2019 10:05
    Aftellen voordat koers op 200 euro staat (uiterlijk deze maand).

    www.finanznachrichten.de/nachrichten-...

    Listed below are some of the companies that are expected to report their phase III clinical trial results *this month (if the companies stick to their timeline).

    Galapagos NV (GLPG)

    Galapagos is a clinical-stage biotechnology company developing medicines for cystic fibrosis, inflammation, and other indications.

    The Company's lead drug candidate is Filgotinib, a highly selective JAK1 inhibitor. Filgotinib is being evaluated in phase III programs in rheumatoid arthritis, Crohn's disease and ulcerative colitis, and in phase II studies in small bowel Crohn's disease, fistulizing Crohn's disease, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis.

    Watch out for.

    Top-line results from phase III trials of Filgotinib in rheumatoid arthritis, dubbed FINCH 1 and FINCH 3, are expected this month.
  8. [verwijderd] 4 maart 2019 13:29
    quote:

    inspirator schreef op 1 maart 2019 00:24:

    These 10 New Drugs Expected In 2019 Are On The Blockbuster Track

    A series of drugs expected to launch in 2019 could become blockbuster drugs in the next five years, according to a recent report.

    Inflammation: A Key Area For Blockbuster Drugs?

    Inflammation drugs are expected to account for nearly half of that $18 billion-plus in 2024 sales from expected blockbuster drugs.

    AbbVie (ABBV) and Gilead Sciences (GILD) with its partner Galapagos (GLPG) are going up against one another with experimental drugs called upadacitinib and filgotinib.

    Both belong to a class known as janus kinase 1 inhibitors, or JAK1 inhibitors. These drugs aim to block a pathway tied to inflammation in the body.

    AbbVie's upadacitinib is already under review at the FDA as a rheumatoid arthritis treatment. The pharma giant is also studying upadacitinib in eczema, Crohn's disease, psoriatic arthritis, ulcerative colitis and axial spondyloarthritis, a series of chronic inflammatory diseases.

    Fastest Mover

    Gilead and Galapagos are furthest along in testing filgotinib in rheumatoid arthritis, ulcerative colitis and Crohn's disease. But the duo is also looking at the JAK1 inhibitor as a potential treatment for eight other diseases.

    EvaluatePharma estimates upadacitinib could bring in $2.18 billion in 2024 sales, with filgotinib trailing at $1.49 billion.

    www.investors.com/news/technology/new...
    Het blockbuster geneesmiddel Filgotinib van Galapagos/Gilead staat klaar om de hoek !
  9. [verwijderd] 5 maart 2019 11:35
    Gilead heeft een oorlogskas van 25 billion dollar beschikbaar.
    Indien de helft wordt besteed aan overname van Galapagos dan overnamebod op Galapagos van 235 euro per aandeel

    Biotech stocks are going wild, and these two could be your best bet for a bigger breakout
    PUBLISHED MON, MAR 4 2019

    It has a war chest of a balance sheet with about $20 billion, $25 billion in cash. They’re making a play on oncology and they have more money to throw at future acquisitions to really buy their top-line growth,

    www.cnbc.com/2019/03/04/these-two-bio...
  10. [verwijderd] 9 maart 2019 10:16
    Clinical efficacy of new JAK inhibitors under development.

    From the new generation JAK inhibitors (see Table 1 for a summary of currently published trials in RA patients), filgotinib and upadacitinib seem to be very promising for treating RA. Fast and profound efficacy is demonstrated as with tofacitinib and baricitinib and long-term efficacy is looked for in currently running long-term follow-up of phase II trials. Both drugs are currently being tested in an extensive phase III program as well in MTX (as biologic)-insufficient responders but also in DMARD-naïve patients. These phase III trials have a classical design, and an active biologic comparator is also included. Peficitinib phase III is running in south-east Asia only.

    Filgotinib

    In vitro assays indicated a selective inhibition of JAK1 and JAK2 over JAK3 and TYK2, and specifically in whole blood assays, a selectivity of ~30-fold for JAK1 over JAK2 was revealed. Details of the in vitro assays used for determining JAK selectivity are discussed by Van Rompaey et al. in their preclinical work on filgotinib [7]. Oral dosing of GLPG0634 (filgotinib) in a therapeutic set-up in a collagen-induced arthritis model in rodents resulted in a significant dose-dependent reduction of the disease progression. Paw swelling and inflammatory cell infiltration, and bone and cartilage degradation were reduced in a similar way compared with etanercept [7].

    In two 4-week double blind, placebo controlled phase IIa trials [8], RA patients with an insufficient response to MTX received filgotinib daily, at doses ranging from 30 to 300 mg or placebo on top of MTX, to explore safety, efficacy, pharmacokinetics and pharmacodynamics. Early efficacy was noted from a dose of 75 mg daily upwards, and the pharmacokinetics of filgotinib and its JAK1 selective active metabolite was dose-proportional over the 30–300 mg range. Safety issues were not encountered and specifically anaemia, which might be the consequence of JAK2 inhibition, was not seen. Based on additional pharmacokinetics and pharmacokinetics/pharmacodynamics modelling of filgotinib [9], daily doses from 50, 100 and 200 mg were tested in two large phase IIb placebo-controlled studies in combination with MTX [10] and as monotherapy [11]. In DARWIN 1 (filgotinib added to MTX, 594 patients) the three doses tested were administered once daily and twice daily. Rapid onset of action (depending on the outcome studied, statically significant differences for 100 mg once and twice daily and 200 mg once daily doses compared with placebo were shown between week 1 and 2) and dose-dependent responses were observed for most efficacy end points. Interestingly, improvements in inflammatory parameters and in signs and symptoms were associated with a dose-dependent increase in haemoglobin. Interestingly also dose-dependent decreases in mean absolute platelet counts were noted (the latter not observed in for instance baricitinib trials). Statistically significant differences for most 100 and 200 mg daily dose groups compared with placebo at week 12 for ACR20 (primary outcome), but also ACR50 and other secondary outcomes, were maintained until week 24. No statistically significant differences between once-daily and twice-daily regimens were seen regarding efficacy. While treatment emergent adverse events (AEs) related to study treatment occurred more frequently in the filgotinib groups compared with placebo, few led to discontinuation of therapy. Infections leading to discontinuation were equally spread over all dose groups including placebo, as were the five herpes zoster infections that all resolved without problems. Dose-dependent decreases in leucocyte counts were seen up to week 4 and appeared to plateau afterwards in most patients. Natural killer (NK) cells did not alter. Up to week 4, as with other JAK inhibitors, dose-dependent increases in mean serum creatinine concentrations were observed in filgotinib-treated patients. Up to week 4, dose-dependent increases in both high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol were observed in all filgotinib groups, which stabilized thereafter. The LDL: HDL ratio decreased over this period. In the DARWIN 2 monotherapy study (283 patients) essentially the same efficacy dynamics were seen. Also here we note an increase in haemoglobin, comparable infection rates and also no tuberculosis or opportunistic infections as in DARWIN 1. Most patients from both phase IIb studies are being followed in a long-term extension, with recently reported data up till week 84 [12] with no new safety issues occurring. Filgotinib 100 and 200 mg once daily is currently being evaluated in a large phase III program.

    academic.oup.com/rheumatology/article...
  11. [verwijderd] 9 maart 2019 12:47
    3 Top Biotech Stocks to Buy in March
    These three healthcare gems have the full attention of our team of experts.

    Brian Feroldi, Chuck Saletta, And Todd Campbell (TMFTypeoh)
    Mar 9, 2019 at 6:00AM

    Galapagos): This foreign-based biotech might not be on your radar. If it isn't, it should be. The company expects data on its lead drug candidate soon, and if the data is positive, it could represent a multibillion-dollar opportunity for the company and its collaboration partner Gilead Sciences (NASDAQ:GILD).

    The two companies have already reported that their rheumatoid arthritis drug filgotinib effectively improved symptoms on a common scoring method in one trial last fall. Results from two additional phase 3 trials that could support filings for approval in the U.S. and Europe are expected before the end of March. If the trials read out similarly to the first trial, then an application for approval could get filed in both markets before the end of this year, clearing the way for commercial sales sometime in 2020.

    There are about 1.5 million people diagnosed with rheumatoid arthritis in the U.S. alone, and existing treatments can cost tens of thousands of dollars annually. As a result, this indication has spawned a slate of megablockbuster medications, including Humira, the world's best-selling drug with over $19 billion in sales per year. Galapagos and Gilead Sciences think filgotinib could be a more effective and safer option than existing treatments. If they're right, then filgotinib's commercial opportunity may be massive.

    Success would benefit Gilead Sciences most, but it will move the needle more for Galapagos. If it is eventually approved, it will be Galapagos' first commercial drug. A win could net Galapagos up to $1.35 billion in milestones from Gilead Sciences, plus Galapagos can pocket royalties on U.S. sales ranging between 20% and 30%. In Europe, the companies will split profits equally.

    Given that Galapagos' market cap is only $5 billion, positive trial results could cause its shares to rally sharply higher. However, there's no guarantee of success, so only risk-tolerant investors should consider buying it before the data is unveiled.

    www.fool.com/investing/2019/03/09/3-t...
  12. [verwijderd] 16 maart 2019 18:32

    The spotlight has shifted to filgotinib!

    Gilead CEO Milligan capped a rocky year — and his career — with the new #1 compensation package in the big leagues of biopharma

    by john carroll — on March 16, 2019 12:27 PM EDT
    Updated: 12:50 PM

    PDF
    PDF

    Gilead’s recently departed CEO John Milligan capped a year marked by setbacks, a major write-off and big questions about the company’s future under a new helmsman with what currently stands as the biggest pay package of all the major league CEOs in biopharma.

    In a new SEC filing, the company outlined how Milligan capped a $1.5 million salary with $21 million in stock awards and options, bringing his full pay packet for 2018 to $26 million. That easily dwarfs the former number 1 on this list — AbbVie CEO Richard Gonzalez and his compensation package of $21.3 million. Emma Walmsley, the lone female CEO on this list, earned less than $8 million at GSK.

    These are chart-topping numbers for Milligan, who grabbed $15.4 million in 2017 and $14 million the year before — more in line with the average CEO pay we’re seeing in the big leagues this year.

    Even so, Milligan’s number for 2018 falls short of the compensation package Gilead used to woo Daniel O’Day away from his senior post at Roche. If you add up his special stock awards and a bonus of up to 150% of his $1.6 million base salary, O’Day stands to earn close to $31 million in his first year, a significant portion of which was used as a make-good payment to cover what he’s leaving behind at Roche.

    Gilead R&D chief John McHutchison, meanwhile, garnered $7.3 million in compensation for 2018. He was named CSO in March in the wake of Norbert Bischofberger’s departure to jump into a startup of his own.

    Milligan ended his 28-year career at Gilead with a distinctly mixed rep for his brief, 2-year stint at the top, which he gained after John Martin stepped over to the chairman’s job. The hep C franchise they built overnight was melting away and his signature move — the $12 billion Kite buyout — put them in the lead with a pioneering cell therapy that doesn’t make a lot of money.

    Milligan bet big on CAR-T, but the company had to write off $820 million against a weak pipeline program they acquired with Kite. And recently Gilead had to acknowledge that selonsertinb, one of its top late-stage prospects, had failed its pivotal study for NASH. The spotlight has shifted to filgotinib, which hopes to compete in an intensely competitive field.

    On the brighter side, Gilead’s HIV franchise — the biotech’s foundation operation — was given a long-term lease on a blockbuster future with new, easier-to-use therapies.
  15. [verwijderd] 23 maart 2019 20:09
    Zojuist heeft Inspirator gesolliciteerd op deze Filgotinib/Gilead functie:

    Job Description
    BU Head Inflammation

    We are looking for a Business Unit Head who will be based in our French affiliate located in Paris and will lead and manage the launch of the oral JAK-inhibitor therapy in Rheumatology and IBDs businesses.
    The BU Lead will have overall responsibility for Strategy, Sales & Marketing and will lead the cross-functional team to launch Gilead into a new business forward, for dedicated Business Unit reporting to the General Manager and being part of the Country Leadership team.

    gilead.wd1.myworkdayjobs.com/en-US/gi...
  16. forum rang 4 Lang 23 maart 2019 20:21
    quote:

    inspirator schreef op 23 maart 2019 20:09:

    Zojuist heeft Inspirator gesolliciteerd op deze Filgotinib/Gilead functie:

    Job Description
    BU Head Inflammation

    We are looking for a Business Unit Head who will be based in our French affiliate located in Paris and will lead and manage the launch of the oral JAK-inhibitor therapy in Rheumatology and IBDs businesses.
    The BU Lead will have overall responsibility for Strategy, Sales & Marketing and will lead the cross-functional team to launch Gilead into a new business forward, for dedicated Business Unit reporting to the General Manager and being part of the Country Leadership team.

    gilead.wd1.myworkdayjobs.com/en-US/gi...
    Zal een goed woordje voor je doen..
  20. [verwijderd] 27 maart 2019 08:22
    Van Flashcrash naar squeeze.

    Er is gisteren flink misbruik gemaakt van onze (onbetrouwbare) banken om stoplosses aan te tikken in periode met vacuum nieuws.
    Ook Onno vd Stolpe mag dit zich aanrekenen.

    Nu dat zwaartekrachtwerking op koers Galapagos uit de lucht is; kan koers naar 200 euro.
    De markt gaat zijn werking doen: een squeeze volgt.

    Raised price target for Gilead Sciences (GILD) to $92 after increasing its peak 2027 filgotinib sales estimate from $2.75B to $4.0B

    Val van 5% maandag en 7,6% dinsdagochtend. De actie van Galapagos is misbruikte aandelenmarkt. Beleggers verwachten belangrijke resultaten van klinische proeven voor het vlaggenschipproduct van Biotech.
    Op maandag verloor het aandeel Galapagos GLPG0.00% 5% tijdens de sessie. Rebelote deze dinsdagochtend met een daling van 7,6% tot 78,22 euro en dit in volumes hoger dan gemiddeld. Bij de nadering van de middag was de titel echter grotendeels hersteld. Geen enkele informatie gepubliceerd door deze biotech komt om deze plotselinge druk op de actie te verklaren.
    En dat is waar het probleem ligt. Naarmate de maand maart vordert en ten einde loopt, is er een groeiende bezorgdheid bij beleggers die deze waarde van Bel nauwlettend volgen.
    Galapagos zal inderdaad tegen het einde van het eerste kwartaal belangrijke resultaten publiceren voor zijn vlaggenschipproduct, filgotinib. Ontwikkeld in samenwerking met Gilead GILD0.71%, deze kandidaat-behandeling die deel uitmaakt van de familie van Janus-kinase-remmers (JAK) is gericht tegen ontstekingsziekten.
    Finch 1 en Finch 3

    De verwachte resultaten zijn voor klinische fase III-onderzoeken die in augustus 2016 zijn gestart, Finch 1 en Finch 3, waarbij de werkzaamheid en veiligheid van twee verschillende doses filgotinib die aan patiënten met reumatoïde artritis (reuma) zijn toegediend, worden getest.
    Finch 1 is een gerandomiseerde studie met 1.650 patiënten. Het is gebaseerd op een placebo en een concurrent van filgonitib, AbbVie humira in combinatie met methotrexaat, een behandeling voor reumatoïde artritis. Finch 3, van zijn kant, tests met 1200 patiënten filgotinib alleen of met methotrexaat.
    De eerste gegevens van de Finch 2-studie zijn al vrijgegeven, wat de werkzaamheid en veiligheid van het Galapagos-product bevestigt.
    Focus op veiligheid

    Wanneer de resultaten van Finch 1 en 3 uiteindelijk openbaar worden gemaakt, zal de nadruk liggen op de effectiviteit van het product, maar vooral op het veiligheidsprofiel (in termen van diepe veneuze trombose en infecties) dat het verschil zou kunnen maken in vergelijking met andere JAK-remmers in ontwikkeling of die al op de markt zijn.
    Twee JAK-remmers zijn al beschikbaar. Dit zijn Pfizer's Xeljanz en Olumiant ontwikkeld door Eli Lilly. De eerste bracht in 2017 1,3 miljard euro omzet op.

    www.lecho.be/dossier/biotechs/petit-f...
957 Posts
Pagina: «« 1 ... 37 38 39 40 41 ... 48 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Weinig houvast voor beleggers in Galapagos

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Galapagos Nieuws

  1. 12 apr KBC Securities verlaagt koersdoel Galapagos naar 50 euro
  2. 05 apr Galapagos toont innovatieve aanpak in hematologische kankerzorg
  3. 23 feb AEX op de waakvlam het weekend in, koersdreun Besi, Alfen en Galapagos 2
  4. 23 feb Beursblik: gebrek aan opwaarts potentieel voor Galapagos op korte termijn
  5. 23 feb Gaat AEX op recordjacht of gaat de beursweek uit als een nachtkaars?
  6. 23 feb Update : Galapagos voldoet aan verwachtingen
  7. 19 feb Beursblik: cashburn belangrijk voor Galapagos
  8. 15 feb Galapagos presenteert nieuwe onderzoeksdata op EBMT-EHA bijeenkomst
  9. 01 feb Galapagos rondt Jyseleca-transactie af
  10. 04 jan Galapagos in zee met Thermo Fisher

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!